Printer Friendly

ADRIA LABORATORIES REPRESENTATIVES AVAILABLE FOR COMMENT

 ADRIA LABORATORIES REPRESENTATIVES AVAILABLE FOR COMMENT
 WHAT: The FDA Antiviral Drug Advisory Committee will meet to evaluate the clinical study results submitted for MYCOBUTIN(TM) (rifabutin), which is currently under review for the prevention of AIDS- related Mycobacterium avium complex (MAC).
 WHY: MAC is a life-threatening bacterial infection experienced by 50 percent of all people with AIDS (PWAs) within 2-1/2 years after their AIDS diagnosis and is believed to be a major cause of wasting among PWAs. There is presently no approved therapy for the prevention or treatment of MAC.
 WHEN: Thursday, Sept. 24, 1992
 8 a.m. to 1 p.m.
 WHERE: Gaithersburg Marriott Hotel
 620 Perry Parkway
 Gaithersburg, Md. 20877
 301-977-8900
 WHO: Two representatives from Adria Laboratories will be available for one-on-one interviews immediately following the meeting:
 -- Joseph Bianchine, M.D., Ph.D., vice president and director,


Medical Research Center
 -- Larry Versteegh, Ph.D., vice president, Regulatory and


Scientific Affairs
 They will be able to discuss MAC and MYCOBUTIN as well as the implications of the committee's decision.
 NOTE: If you are unable to attend, you can hear the committee meeting by phone through Hearings-on-the-Line. For access and pricing information call 202-966-2211
 CONTACT: Karin Leuffgen of Porter/Novelli, 212-315-8231, for Adria Laboratories.
 -0- 9/21/92


CO: Adria Laboratories ST: Maryland IN: MTC SU:

SM-SH -- NY078 -- 1809 09/21/92 15:41 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 21, 1992
Words:226
Previous Article:/ C O R R E C T I O N -- FOOD LION/
Next Article:SEARLE MEDICAL EXECUTIVE RECEIVES PRESTIGIOUS AWARD FROM AMERICAN COLLEGE OF CLINICAL PHARMACOLOGY
Topics:


Related Articles
IMMUNOGEN EXPANDS MANAGEMENT TEAM: DONALD J. MCCARREN NAMED PRESIDENT AND CHIEF OPERATING OFFICER
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF MYCOBUTIN(TM) FOR THE PREVENTION OF AIDS-RELATED INFECTION
ADRIA LABORATORIES AND SMITHKLINE BEECHAM AGREE TO CO-PROMOTE MYCOBUTIN
ADRIA ANNOUNCES FINALIZATION OF MYCOBUTIN CO-PROMOTION AGREEMENT
PHS TASK FORCE RECOMMENDS PROPHYLAXIS AGAINST AIDS-RELATED INFECTION WITH MYCOBUTIN
WILLIAM ROHN JOINS IDEC PHARMACEUTICALS AS SENIOR VICE PRESIDENT, COMMERCIAL AND CORPORATE DEVELOPMENT
FEDERAL TASK FORCE ANNOUNCES PREVENTION AND TREATMENT RECOMMENDATIONS FOR AIDS-RELATED INFECTION
PROCORDIA ANNOUNCES NEW HEALTH CARE ORGANIZATION IN THE U.S.
PROCORDIA SHAREHOLDERS CREATE PHARMACIA
Novavax Appoints James R. Mirto as Vice President And Chief Operating Officer.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters